UNIVERSITY OF PENNSYLVANIA - SCHOOL OF MEDICINE
Curriculum Vitae

June, 2017

Alan Richard Cohen, M.D.

Home Address: 315 South 25th Street
Philadelphia, PA 19103

Office Address: Leonard & Marilyn Abramson Pediatric Research Building
The Children's Hospital of Philadelphia
Room 1416
34th Street and Civic Center Boulevard
Philadelphia, Pennsylvania 19104

Education:

1964-1968	B.A. Harvard University (Magna cum laude)
1968-1972	M.D. University of Pennsylvania School of Medicine

Postgraduate Training and Fellowship Appointments:

1972-1973	Internship, The Children's Hospital of Philadelphia
1973-1974	Assistant Chief Resident, The Children's Hospital of Philadelphia
1974-1975	Chief Resident, The Children's Hospital of Philadelphia
1975-1978	Hematology-Oncology Fellowship, The Children's Hospital of Philadelphia

Faculty Appointments:

1977-1978	Clinical Associate in Pediatrics, University of Pennsylvania School of Medicine
1978-1984	Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine
1984-1990	Associate Professor of Pediatrics, University of Pennsylvania School of Medicine
1990-	Professor of Pediatrics, Clinician-Educator Track University of Pennsylvania School of Medicine
2001-2013	Chairman, Department of Pediatrics University of Pennsylvania School of Medicine

Hospital and Administrative Appointments:

1978-1982	Assistant Physician, The Children's Hospital of Philadelphia
1982-1985	Associate Physician, The Children's Hospital of Philadelphia
1985-	Senior Physician, The Children's Hospital of Philadelphia
1978-1988	Director, Hematology and Coagulation Laboratories, The Children's Hospital of Philadelphia
1986-1990	Director of Clinical Activities, Division of Hematology, The Children's Hospital of Philadelphia
1990-1992	Acting Chief, Division of Hematology, The Children's Hospital of Philadelphia
1992-2001	Chief, Division of Hematology, The Children's Hospital of Philadelphia

1994-	Senior Member, Joseph Stokes, Jr. Research Institute, The Children's Hospital of Philadelphia
2001-2013	Physician-in-Chief, The Children's Hospital of Philadelphia Leonard & Madlyn Abramson Endowed Chair in Pediatrics, The Children's Hospital of Philadelphia
2013-	Medical Advisor to the Chief Executive Officer The Children's Hospital of Philadelphia

Specialty Certification:

1973	National Board of Medical Examiners
1977	American Board of Pediatrics: Pediatrics
1978	American Board of Pediatrics: Hematology-Oncology
1993	Recertification – American Board of Pediatrics: Hematology-Oncology
2003	Recertification – American Board of Pediatrics: Hematology-Oncology
2013	Recertification – American Board of Pediatrics: General Pediatrics

Licensure: Pennsylvania

Awards, Honors and Membership in Honorary Societies:

1968	Phi Beta Kappa
1971	Alpha Omega Alpha
1985	Christian R. and Mary F. Lindback Award for Distinguished Teaching
1985	Residents' Annual Teaching Award
1998	Dripps Memorial Award for Excellence in Graduate Medical Education
2004	American Academy of Pediatrics, Pennsylvania Chapter, Pediatrician of the Year Award

Memberships in Professional and Scientific Societies:

National Societies:
- American Pediatric Society
- Society for Pediatric Research
- American Society of Hematology
- American Academy of Pediatrics
- American Society of Pediatric Hematology-Oncology
  - (President, 1997-1999)
  - (Board of Trustees, 1995-2001)
- Cooley's Anemia Foundation
  - (Chair, Medical Advisory Board, 1992-2003)
- Thalassaemia International Federation Scientific Advisory Board
- American Board of Pediatrics
  - Subboard of Pediatric Hematology-Oncology
    - Member, 2001 – 2006

(Chair, 2004-2006)

Board of Directors, 2006-2012
(Chair, 2010-2011)
Finance Committee, 2007-2011
(Chair, 2008-2009)
Credentials Committee, 2013-
Dragonfly Forest, Inc. Board
Member, 2006 -2010
Association of Medical School Pediatric Department Chairs (AMSPDC)
(President Elect, 2009-2011)
(President, 2011-2013)
(Immediate Past-President, 2013-2014)

Local Societies
Philadelphia Pediatric Society
Philadelphia Hematology Society
(Secretary-Treasurer, 1979-1986)

Editorial Positions:

Editorial Board, American Journal of Pediatric Hematology/Oncology (1998-2008)
Editorial Board, Haematologica (1997 – 2001)
Reviewer for Pediatrics, Haematologica, Blood, American Journal of Hematology, American Journal of Pediatric Hematology/Oncology, Journal of Pediatrics, New England Journal of Medicine, Pediatric Blood & Cancer

Academic Committees at the University of Pennsylvania and Affiliated Hospitals:

1982-1992	Pediatrics Residency Advisory Committee (Chairman, 1986-1992)
1985-2000	Teaching Awards Committee
1989-1992	Subcommittee for Evaluation
1995-1996	Integrative Neuroscience Course Review
2012-2013	Review of Department of Medicine
2014-	Residency Mentoring Committee (CHOP)
2014-	Intern Selection Committee (CHOP)
2014-	Conflict of Interest Committee, Chair (CHOP)
2015-	Hematology-Oncology Fellowship Committee (CHOP)
2015-	Committee on Academic Freedom and Responsibility

Major Teaching and Clinical Responsibilities at the University of Pennsylvania and Affiliated Hospitals:

1. Medicine 100 (formerly ID 103), Director, Pediatric Physical Diagnosis Course for first-year medical students, 1981-1986
2. Pediatrics 200, 1 month each year, 1979-
3. Pediatrics 300, 1 month each year, 1979-
4. Pediatrics 324, elective in Pediatric Hematology, 1979-present, course director, 1985-2001
5. Hematology attending rounds, 2-3 months each year (CHOP), 1978 -
6. Hematology Clinic, 1 day each week (CHOP), 1978 -

Lectures by Invitation (past 3 years):

February, 2013	"Hemoglobinopathies and Iron Overload: Scientific Advances and Ethical Setbacks." Grand Rounds, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
March, 2014	"When the Solution is the Problem: Transfusion-Derived Iron Overload." Global Iron Summit, Athens, Greece
January, 2015	"Medical Education in the United States" and "Teaching and Supervising Research" Conference on Education, Bangkok, Thailand.
March, 2015	"How Much of a Threat is Iron Overload in Sickle Cell Disease?" Global Iron Summit, Berlin, Germany
March, 2016	"Thalassemia Patients: Are We Transfusing Them Effectively?" Global Iron Summit, Madrid, Spain

Organizing Roles in Scientific Meetings:

May, 1997	Seventh Cooley's Anemia Symposium, Chairperson, New York Academy of Sciences, Cambridge, Massachusetts
March, 2001	11th International Conference on Oral Chelation in the Treatment of Thalassaemia and Other Diseases, Advisory Board, Catania, Italy
March, 2005	Cooley's Anemia Eighth Symposium (sponsored by the New York Academy of Sciences and the Cooley's Anemia Foundation) Conference Organizer, Lake Buena Vista, Florida
October, 2010	Child Health Research Center (CHRC) 20th Annual Retreat, Philadelphia, PA. (co-organizer)
March, 2012	The 2nd National Conference on Blood Disorders in Public Health, Atlanta, Georgia. (Planning Committee)
March, 2015	Global Iron Summit, Berlin Germany. (Scientific Committee)

Bibliography:

Research Publications, peer reviewed (print or other media):

Cohen A, Schwartz E. Iron chelation therapy with deferoxamine in Cooley's anemia. J Pediatr 92:643-647, 1978.

Cohen A, Schwartz E. Excretion of iron in response to deferoxamine in sickle cell anemia. J Pediatr 92:659-662, 1978.

Cohen A, Schwartz E. Iron chelation therapy in sickle cell anemia. Am J Hematol 7:69-76, 1979.

Cohen A, Markenson AJ, Schwartz E. Transfusion requirements and splenectomy in Cooley's anemia. J Pediatr 97:100-102, 1980.

Cohen A. Effect of time on hematologic values in prediluted capillary and venous blood. Am J Clin Pathol 74:306-307, 1980.

Cohen A, Schwartz E. Decreasing iron stores during intensive chelation therapy. Ann NY Acad Sci 344:405-408, 1980.

Greenberg J, Curtis-Cohen M, Gill FM, Cohen A. Prolonged reticulocytopenia in autoimmune hemolytic anemia of childhood. J Pediatr 97:784-786, 1980.

Poncz M, Colman N, Herbert V, Schwartz E, Cohen A. Therapeutic management of congenital folate malabsorption. J Pediatr 98:76-79, 1981.

Cohen A, Trotzky M, Pincus D. Reassessment of the microcytic anemia of lead poisoning. Pediatrics 67:904-906, 1981.

Cohen A, Cohen I, Schwartz E. Scurvy and altered iron stores in thalassemia major. N Engl J Med 304:158-160, 1981.

Cohen A, Martin M, Schwartz E. Response to long-term deferoxamine therapy in thalassemia. J Pediatr 99:689-694, 1981.

Cohen A. Chelation therapy in the treatment of iron overload. Drug Ther 6:47-58, 1981.

Graziano JH, Piomelli S, Seaman C, Wang T, Cohen A, Kelleher JF, Schwartz E. A simple technique for preparation of young red cells for transfusion from ordinary blood units. Blood 59:865-868, 1982.

Cohen A, Martin M, Schwartz E. Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 58:369-373, 1984.

Cohen A, Schmidt JM, Martin M, Barnsley W, Schwartz E. Clinical trial of young red cell transfusions. J Pediatr 104:865-868, 1984.

Cohen A, Mizanin J, Schwartz E. Treatment of iron overload in Cooley's anemia. Ann NY Acad Sci 445:274-281, 1985.

Nelson L, Elfman J, Cohen A. Management of Ludwig's angina in a patient with severe hemophilia A with factor VIII inhibitors: Report of a case. J Dent Child 52.306-311, 1985.

Poncz M, Greenberg J, Gill FM, Cohen A. Hematologic changes during acute chest syndrome in sickle cell disease. Am J Pediatr Hematol Oncol 7:96-99, 1985.

Hoyt R, Scarpa N, Wilmott RW, Cohen A, Schwartz E. Pulmonary function abnormalities in homozygous beta thalassemia. J Pediatr 109:452-455, 1986.

Cohen A, Seidl-Friedman J. HemoCue system for hemoglobin measurement: evaluation in anemic and non-anemic children. Am J Clin Pathol 90:302-305, 1988.

Schwartz E, Cohen A, Surrey S. Overview of the beta thalassemias: Clinical and genetic aspects. Hemoglobin 12:551-564, 1988.

Michelson A, Cohen, A. Incidence and treatment of fractures in thalassemia. J Ortho Trauma 2:29-32, 1988.

Cohen A, Gayer R, Mizanin J. Long-term effect of splenectomy on transfusion requirements in thalassemia major. Am J Hematol 30:254-256, 1989.

Manno CS, Cohen AR. Splenectomy in spherocytosis: Is it worth the risk? Am J Pediatr Hematol/Oncol 11:300-303, 1989.

Cohen AR, Mizanin J, Schwartz E. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J Pediatr 115:151-155, 1989.

Goedert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, White GC, Drummond JE, Vaidya K, Mann DL, Eyster ME, Ragni MV, Lederman MM, Cohen AR, Bray GL, Rosenberg PS, Friedman RM, Hilgartner MW, Blattner WA, Kroner B, Gail MH. Rates, markers and cofactors of human immunodeficiency virus type I infection and AIDS in subjects with hemophilia. N Engl J Med 321:1141-1148, 1989.

Spear ML, Spear M, Cohen AR, Pereira GR. Effect of fat infusions on platelet concentration in premature infants. J Parenter Enteral Nutr 14(2):165-168, 1990.

Cohen A, Martin M, Mizanin J, Konkle DF, Schwartz E. Vision and hearing during deferoxamine therapy. J Pediatr 117:326-30, 1990.

Cohen A, Martin M, Ohene-Frempong, K. Increased blood requirements during long-term transfusion therapy in sickle cell disease. J Pediatr 118:405-407, 1991.

Young TL, Schaffer DB, Cohen AR. Infantile glaucoma associated with the Diamond-Blackfan syndrome. J Pediatr Ophthal Strab 29:55-58, 1992.

Rabkin CS, Hilgartner MW, Cohen AR, Goedert JJ. Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA 267:1090-94, 1992.

Burk CD, Miller L, Handler SD, Cohen AR. Pre-operative history and coagulation screening in children undergoing tonsillectomy. Pedatrics 89:691-695, 1992.

Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwartz E. A modified transfusion program for prevention of stroke in sickle cell disease. Blood 79:1657-1661, 1992.

Rackoff WR, Ohene-Frempong K, Month S, Scott JP, Neahring B, Cohen AR. Neurologic events after partial exchange transfusion for priapism in sickle cell disease. J Pediatr 120:882-885, 1992.

Brittenham GM, Cohen AR, McLaren, CE, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrell DE, Harris JW. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 42:81-85, 1993.

Manno CS, Butler RB, Cohen AR. Low recovery in vivo of highly purified factor VIII. J Pediatr 121:814-818, 1992.

Eyster ME, Rabkin CS, Cohen AR, Goedert JJ. Human immunodeficiency virus-related conditions in children and adults with hemophilia: rates, relationship to CD4 counts, and predictive value. Blood 81:828-834, 1993.

Olivieri NF, Nathan DG, MacMillan JH, Wayne A, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331:574-578, 1994.

Kim HC, Dugan NP, Silber JH, Martin MB, Schwartz E, Ohene-Frempong K, Cohen AR. Erythrocytapheresis therapy for reduction of iron overload in chronically transfused patients with sickle cell disease. Blood 83:1136-1142, 1994.

Goedert JJ, Cohen AR, Kessler CM, Eichinger S, Seremetis SV, Rabkin CS, Yellin FJ, Rosenberg PS, Aledort LM. Risks of immune deficiency, AIDS and death by purity of factor VIII concentrate. Lancet 344:791-792, 1994.

Maris JM, Butler RB, Cohen AR. Loss of detectable antibody to the hepatitis B surface antigen in previously immunized HIV negative hemophiliacs. J Pediatr 126:269-271, 1995.

Lederman MM, Jackson JB, Kroner BL, White GC, Eyster ME, Aledort LM, Hilgartner MW, Kessler CM, Cohen AR, Kiger KP, Goedert JJ. Human immunodeficiency virus (HIV) Type I infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacs. J Infect Dis 172:228-231, 1995.

Cohen AR, Martin MB, Schwartz E. Hydroxyurea therapy in thalassemia intermedia. Colloque Inserm 234:193-194, 1995.

Pearson HA, Cohen A, Giardina PV, Kazazian HH. The changing profile of homozygous beta thalassemia. Pediatrics 97:352-356, 1996.

O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, Cohen AR, Luban N, Hatzakis A, Aledort LM, Rosenberg PS, Miley WJ, Kroner BL, Goedert JJ. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA 276:105-110, 1996.

Ludlow LB, Schick BP, Budarf ML, Driscoll DA, Zackai EH, Cohen A, Konkle BA. Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibb promoter resulting in the Bernard-Soulier Syndrome. J Biol Chem 271:22076-22080, 1996.

Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr 130:86-88, 1997.

Kattamis AC, Shankar S, Cohen AR. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenous immunoglobulin G. J Pediatr 130:281-283, 1997.

Kelly KM, Butler, RB, Farace L, Cohen AR, Manno CS. Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A. J Pediatr 130:537-540, 1997.

Levine JE, Cohen AR, McQueen M, Martin M, Giardina PJ. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment. Am J Pediatr Hematol/Oncol 19:139-141, 1997.

Camaschella C. Kattamis A, Petroni D, Roetto A, Sivera P, Sbaiz L, Cohen A, et al. Different hematological phenotypes caused by the interaction of triplicated a-globin genes and heterozygous b-thalassemia. Am J Hematol 55:83-88, 1997.

Nuss R, Stultz J, Ramafedi G, Lloyd Schultz S, Cohen A. Health care provider and self-assessment of health status and sexual behaviour in HIV-seropositive young men with haemophilia. Haemophilia 3:270-276, 1997.

Michaels LA, Cohen AR, Zhao H, Raphael RI, Manno CS. Screening for hereditary spherocytosis using automated erythrocyte indices. J Pediatr 130:957-960, 1997.

Larson P, Friedman D, Reilly M, Kattamis A, Asakura T, Fortina P, Cohen A, Kim H, Manno C. The presurgical management of a patient with a high oxygen affinity, unstable hemoglobin variant (Hb Bryn Mawr) with erythrocytapheresis. Transfusion 37:703-707, 1997.

Cohen A, Galanello R, Piga A, Vullo C, Tricta F. A multi-center safety trial of the oral iron chelator deferiprone, Ann NY Acad Sci 850:223-226, 1998.

Nguyen GT, Carrington M, Beeler JA, Dean M, Aledort LM, Blatt PM, Cohen AR, O'Brien TR. Phenotypic expressions of *CCR5-D32/D32* homozygosity. J Acquir Immune Defic Syndr 22:75-82, 1999.

Kwiatkowski JL, West TB, Heidary N, Smith-Whitley K, Cohen AR. Severe iron deficiency anemia in young children. J Pediatr 135:514-516, 1999.

Cohen AR, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: A multi-center study. Br J Haematol 108:305-312, 2000.

Vesely S, Buchanan GR, Cohen A, Raskob G, George J. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: Results of a survey of practicing pediatric hematology-oncology specialists. J Pediatr Hematol/Oncol 22:55-61, 2000.

Vesley S, Buchanan GR, Adix L, George JN, Cohen AR, Blanchette VS, Kuhne T. Self-reported initial management of childhood idiopathic thrombocytopenic purpura: Results of a survey of members of the American Society of Pediatric Hematology/Oncology. J Pediatr Hematol/Oncol 25:130-133, 2001.

Kulkarni R, Aledort LM, Berntorp E, Brackman HH, Brown D, Cohen AR, Ewing NP, Gringeri A, Gruppo R, Hoots K, Leissenger C, Peerlinck K, Poon M, Wong W. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol 67:240-246, 2001.

Wang ZJ, Haselgrove JC, Martin MB, Hubbard AM, Li S, Loomes K, Moore JR, Zhao H, Cohen AR. Evaluation of iron overload by single voxel MRS measurement of liver T2. JMRI 15:395-400, 2002.

Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, de Moerloose P, White GC, Angiolillo A, Luban NLC, Sherman KE, Manco-Johnson M, Preiss L, Leissinger C, Kessler

CM, Cohen AR, DiMichele D, Hilgartner MW, Aledort LM, Kroner BL, Rosenberg PS, Hatzakis A. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 100:1584-1589, 2002.

Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 100:1566-1569, 2002.

Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload: Blood 102:17-24, 2003.

Patterson M, Walker L, Chui DHK, Cohen AR, Waye JS. Identification of a new β-thalassemia nonsense mutation [Codon 59 (AAG→ TAG)]. Hemoglobin 27:201-203, 2003.

Cohen AR, Galanello R, Piga A, DeSanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102:1583-1587, 2003.

Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood 104:34-39, 2004.

Chou ST, Shah SS, Hodinka RL, Cohen AR. Positive heterophile antibody test and massive splenomegaly in an adolescent with previously unsuspected Gaucher disease. Pediatr Emerg Care 20:181-184, 2004.

Chu Z, Cohen AR, Muthupillai R, Chung T, Wang ZJ. MRI measurement of hepatic magnetic susceptibility — phantom validation. Magnetic Resonance in Medicine 52:1318-1327, 2004.

Wang ZJ, Lian L, Chen Q, Zhao H, Asakura T, Cohen AR. 1/T2 and magnetic susceptibility measurements in a gerbil cardiac iron overload model. Radiology 234:749-755, 2005.

Armanios M, Chen JL, Chang, YC, Brodsky RA, Hawkins A, Griffin CA, Eshleman JR, Cohen AR, Chakravarti A, Hamosh A, Greider CW. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci USA 102:15960-15964, 2005.

Borgna-Pignatti C, Ventola M. Friedman D, Cohen AR, Origa R, Galanello, R, Lindeman R, Francis S, Reverberi R, Volpato S. Seasonal variation of pre-transfusion hemoglobin levels in patients with thalassemia major. Blood 107:355-357, 2006.

Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, Cohen A, Neufeld E, Giardina PJ. Prevalence of fractures among the thalassemia syndromes in North America. Bone 38:571-575, 2006.

Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattarnis A, Yurdanur K, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G,

Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 107:3455-3462, 2006.

Manco-Johnson, MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemaophilia. NEJM 357:535-544, 2007.

Song R, Cohen AR, Song HK. Improved transverse relaxation rate measurement techniques for the assessment of hepatic and myocardial iron content. J Magn Reson Imaging 26: 208-214, 2007.

Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in ß-thalassemia major. Blood 111:583-587, 2008.

He T, Kirk P, Firmin DN, Lam WM, Chu WC, Au WY, Chan GC, Tan RS, Ng I, Biceroglu S, Aydinok Y, Fogel MA, Cohen AR, Pennell DJ. Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment. J Cardiovasc Magn Reson. 10:11, 2008.

Kirk P, Anderson LJ, Roughton M, Tanner MA, Lam WW, Au WY, Chu WC, Chan G, Galanello R, Matta G, Fogel M, Cohen AR, Tan RS, Chen K, Ng I, Lai A, Fucharoen S, Laothamata J, Chuncharunee S, Jongjirasiri S, Firmin DC, Smith GC, Pennell DJ. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging 32:315-319, 2010.

Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Pga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 118:884-893, 2011.

Neunert C, Lim W, Crowther M, Cohen A, Solberg, Jr., L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guidelines for immune thrombocytopenia. Blood 117:4190-4207, 2011.

Kwiatkowski JL, Cohen AR, Garro J, Alvarez O, Nagasubramanian R, Sarnaik S, Thompson A, Woods GM, Scultz W, Mortier N, Lane P, Mueller B, Yovetich N, Ware RE; for the SWiTCH Study Investigators. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. Am J Hematol 87:221-223, 2012.

Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF,

Neufeld EJ; Thalassemia Clinical Research Network. Chelation use and iron burden in North America and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 119:2746-2753, 2012.

Marx A, Shaw K, Taylor A, Cohen A. Department of Pediatrics Chair's Initiatives: Promoting innovation and improvement through collaboration, accountability, and faculty development. J Pediatr 161:377-378, 2012.

Block RW, Dreyer, BP, Cohen AR, Stapleton FB, Furth SL, Bucciarelli RL. An agenda for children for the 113 Congress: Recommendations from the Pediatric Academic Societies. Pediatrics 131:109-119, 2013.

Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, Hoffman TM, Kiernan MS, Lerakis S, Piga A, Porter JB, Walker JM, Wood J; American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging. Cardiovascular Function and Treatment in Beta-Thalassemia Major: A Consensus Statement. Circulation 128:281-308, 2013.

Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR, Coates T, Boudreaux J, Neufeld EJ, Kenney K, Grant A, Thompson AA, CDC Thalassemia Investigators. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention. Transfusion 54:972-981, 2014.

Aygun B, Mortier NA, Kesler K, Lockhart A, Schultz WH, Cohen AR, Alvarez O, Rogers ZR, Kwiatkowski JL, Miller ST, Sylvestre P, Iyer R, Lane PA, Ware RE; Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) Trial Investigators. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. Br J Haematol 169:262-266, 2015.

Wood JC, Pressel S, Rogers ZR, Odame I, Kwiatkowski JL, Lee MT, Owen WC, Cohen AR, St Pierre T, Heeney MM, Schultz WH, Davis BR and Ware RE. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. Am J Hematol 90: 806-810, 2015.

Ware RE, Davis BR, Schultz WH, Brown, RC, Aygun B, Sarnaik SA, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone CM, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts CW, Heeney MM, Kalfa TA, Nelson SC, Imran H, Nottage KA, Alvarez OA, Rhodes M, Thompson AA, Rothman J, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood JC, Piller L, Wei P, Luden J, Mortier NA, Stuber S, Luban NLC, Cohen AR, Pressel SL, and Adams RJ. TCD with transfusions changing to hydroxyurea (TWiTCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. Lancet 387:661-670, 2015.

Wood JC, Cohen AR, Pressel SL, Aygun B, Imran H, Luchtman-Jones L, Thompson AA, Fuh B, Schultz WH, Davis BR, and Ware RE. Organ iron accumulation in chronically

transfused children with sickle cell anemia: baseline results from the TWiTCH trial. Br J Haematol 172: 122-130, 2016.

Submitted manuscripts:

Taher AT, Saliba AN, Kuo KH, Giardina PJ, Cohen AR, Neufeld EJ, Aydinok Y, Kwiatkowski JL, Chapin JC, Kramer W, Jeglinski BI, Pietropaulo K, Berk G Viprakasit V. A phase 1b study evaluating the safety and pharmacokinetics of SP-4210, a novel iron chelator for transfusional iron overload. Submitted, June 2017.

Vichinsky E, Cohen A, Thompson AA, Giardina PJ, Lal A, Paley C, Cheng WY, McCormick N, Sasane M, Qiu Y, Kwiatkowski JL: Epidemiologic and clinical characteristics of thalassemia intermedia in the United States. Submitted, June 2017.

Contributions to peer-reviewed clinical research publications, participation cited but not by authorship:

Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, Giardina PJ, Vichinsky E, Olivieri N, Alberti D, Holland J, Harmatz P; Thalassemia Clinical Research Network (Cohen AR, collaborator). Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica 93:817-825, 2008.

Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, Giardina PJ, Neufeld EJ, Porter J, Olivieri N; Thalassemia Clinincal Research Network (Cohen AR, collaborator). Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica 93:1247-1251, 2008.

Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, Holm IA, Lane J, Schneider R, Fleisher M, Grady RW, Peterson CC, Giardina PJ; Thalassemia Clinical Research Network (Cohen AR, collaborator). Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24:543-557, 2009.

Vogiatzi MG, Macklin EA, Trachtenberg FL, Fung EB, Cheung AM, Vichinsky E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, Holm IA, Fleisher M, Grady RW, Peterson CM, Giardina PJ; Thalassemia Clinical Research Network (Cohen AR, collaborator). Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol 146:546-556, 2009.

Morris CR, Kim HY, Trachtenberg F, Wood J, Quinn CT, Sweeters N, Kwiatkowski JL, Thompson AA, Giardina PJ, Boudreaux J, Olivieri NF, Porter JB, Neufeld EJ, Vichinsky EP; Thalassemia Clinical Research Network (Cohen AR, collaborator). Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood 118:3794-3802, 2011.

Walter PB, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, Giardina PJ, Grady RW, Vichinsky E, Olivieri N, Trachtenberg F, Alberti D, Fung E, Ames B, Higa

A, Harmatz P; Thalassemia Clinical Research Network (Cohen AR, collaborator). Increased leucocyte apoptosis in transfused β-thalassaemia patients. Br J Haematol 160:399-403, 2013.

Haines D, Martin M, Carson S, Oliveros O, Green S, Coates T, Eile J, Schilling L, Dinu B, Mendoza T, Gerstenberger E, Trachtenberg F, Vichinsky E; Thalassemia Clinical Research Network (Cohen AR, collaborator). Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 160:680-687, 2013.

Oliveros O, Trachtenberg F, Haines D, Gerstenberger E, Martin M, Carson S, Green S, Calamaras D, Hess P, Yamashita R, Vichinsky E; Thalassemia Clinical Research Network (Cohen AR, collaborator). Pain over time and its effects on life in thalassemia. Am J Hematol. 88:939-943, 2013.

Tubman VN, Fung EB, Vogiatzi M, Thompson AA, Rogers ZR, Neufeld EJ, Kwiatkowski JL; Thalassemia Clinical Research Network (Cohen AR, collaborator). J Pediatr Hematol Oncol 37: e162-169, 2015.

Abstracts: (selected from past 5 years)

Wood JC, Cohen A, Aygun B, Imran H, Luchtman-Jones L, Thompson AA, Fuh B, Davis BR, Pressel SL, Schultz WH, Ware RE. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia – baseline findings from the TWiTCH trial. American Society of Hematology Annual Meeting, New Orleans, Louisiana, 2013.

Wood JC. Rogers ZR, Odame I, Kwiatkowski J, Lee M,. Owen WC, Cohen A, St. Pierre, T, Davis BR, Parker C, Schultz WH and Ware RE. Liver iron concentration by MRI in chronically transfused children with sickle cell anemia in the TWiTCH trial. American Society of Hematology Annual Meeting, New Orleans, Louisiana,2013.

Ware WR, Davis BR, Schultz WH, Brown C, Aygun B, Sarnaik SA, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone CM, Lee MT, Kwiatkowski J, Jackson S, Miller ST, Roberts CW, Heeney MM, Kalfa TA, Nelson SC, Imran H, Nottage KA, Alvarez OA, Rhodes M, Thompson AA, Rothman J, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood JC, Piller L, Wei P, Luden J, Mortier NA, Stuber S, Luban NLC, Cohen AR, Pressel SL, and Adams RJ. TCD with transfusions changing to hydroxyurea (TWiTCH): hydroxyurea therapy as an alternative to transfusions for primary stroke prevention in children with sickle cell anemia. American Society of Hematology Annual Meeting (plenary session), Orlando, FL 2015.

Aygun B, Mortier N, Rogers ZR, Owen W, Fuh B, George, A, Kalfa TA, Kwiatkowski J, Lee M, Imran H, Miller ST, Wood JC, Cohen AR, Pressel SL and Ware RE.. Iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell anemia: the TWiTCH Experience. American Society of Hematology Annual Meeting, San Diego, CA, 2016.

Wood JC, St Pierre T, Aygun B, Mortier N, Schultz WH, Piccone CM,, Hankins J, Rogers ZR, Owen W, Odame I, Sarnaik SA, Hilliard L, Cohen AR and Ware RE. Agreement between R2 and R2* liver iron estimates is independent of the type of

iron removal therapy: results from the TWiTCH trial. American Society of Hematology Annual Meeting, San Diego, CA, 2016.

Editorials, Reviews, Chapters, including participation in committee reports (print or other media):

Cohen A, Schwartz E. Comparison of different parenteral routes of deferoxamine administration, in Chelation Therapy in Chronic Iron Overload, Symposia Specialists, Inc., Miami, 1977, pp 81-94.

Cohen A, Schwartz E. Thalassemia, in Brenneman's Practice of Pediatrics, Harper and Row, Inc., Hagerstown, 1989 (revised, 1983).

Cohen A, Schwartz E. Iron overload in children with hemoglobinopathies, in Hemoglobinopathies in Children, Schwartz E, editor, Publishing Sciences Group, Inc., Littleton, 1979.

Cohen A, Schwartz E. Transfusion in the newborn period, in Transfusion Therapy: Fetus, Infant and Child, Cohen A, and Sherwood W, editors, Masson Publishing USA, Inc., New York, 1980.

Cohen A, Sherwood W, Busch S. Transfusion therapy: hemolytic disease of the newborn, in Transfusion Therapy: Fetus, Infant and Child, Sherwood W and Cohen A, editors, Masson Publishing USA, Inc., New York, 1980.

Cohen A, Frasca P, Schwartz E. Normal liver iron stores after long-term chelation therapy in thalassemia, in Structure and Function of Iron Storage and Transport Proteins, Urushizaki I et al, editors, Elsevier Science Publishers, Amsterdam, 1983.

Cohen A, Martin M, Schwartz E. Decreased iron loading with young red cell transfusions, in Structure and Function of Iron Storage and Transport Proteins, Urushizaki I et al, editors, Elsevier Science Publishers, Amsterdam, 1983.

Poncz M, Cohen A, Schwartz E. Thalassemia, in Advances in Pediatrics, Barness L, editor, Yearbook Medical Publishers, Chicago, 1984.

Cohen A, Witzleben C, Schwartz E. Treatment of iron overload. Semin Liver Dis 4:228-238, 1984.

Cohen A. Scurvy, in Conn's Current Therapy, Rakel RE, editor, W.B. Saunders Company, Philadelphia, 1985, 1986.

Cohen A. Transfusion therapy for children and adolescents with hemoglobin disorders, in Hemotherapy in Childhood and Adolescence, Luban NLC and Kolins J, editors, American Association of Blood Banks, Arlington, 1985.

Cohen A. Pallor, in Textbook of Pediatric Emergency Care, Fleisher G, and Ludwig S, editors, Williams and Wilkins, Baltimore, 1987.

Cohen A. Purpura, in Textbook of Pediatric Emergency Care, Fleisher G, and Ludwig S, editors, Williams and Wilkins, Baltimore, 1987.

Cohen A. Hematologic emergencies, in Textbook of Pediatric Emergency Care, Fleisher G, and Ludwig S, editors, Williams and Wilkins, Baltimore, 1987.

Cohen A. Transfusion therapy for disorders of hemoglobin, in Pediatric Transfusion Medicine, Luban NLC and Kasprisin DO, editors, CRC Press, Boca Raton, 1987.

Cohen A. The management of iron overload in the pediatric patient, in Hematology/Oncology Clinics of North America, Oski F, editor, W.B. Saunders Company, Philadelphia, 1987.

Cohen A. Management issues of collaborative clinical studies. Clin Pediatr 26:615-619, 1987.

Cohen A, Surrey S, Schwartz E. Cooley's anemia: Progress in biology and medicine. National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, 1987.

Cohen A. Hematology, in Pediatric Secrets, Polin RA, Ditmar MF, eds, Hanley & Belfus, Inc., Philadelphia, 1989.

Cohen A, Mizanin J, Schwartz E. High-dose intravenous chelation therapy with deferoxamine, in Advances And Controversies In Thalassemia Therapy, Buckner CD, Gale RP and Lucarelli G, editors, Alan R. Liss, Inc., New York, 1989.

Cohen A. Treatment of transfusional iron overload. Am J Hematol/Oncol 12:4-8, 1990.

Cohen A. Current status of iron chelation therapy with deferoxamine. Semin Hematol 27:86-90, 1990.

Cohen A, Martin M, Schwartz E. Current treatment of Cooley's anemia: intravenous chelation therapy. Ann NY Acad Sci 612:286-292, 1990.

Smith KJ, Lusher JM, Cohen AR. Initial clinical experience with a new, pasteurized, monoclonal antibody purified factor VIII:C. Semin Hematol 27:25-30, 1990.

Cohen A. Pallor, in Textbook of Pediatric Emergency Medicine, 3rd edition, Fleisher G, Ludwig eds, Williams and Wilkins, Baltimore, 1993.

Cohen A. Purpura, in Textbook of Pediatric Emergency Medicine, 3rd edition, Fleisher G, Ludwig S, eds, Williams and Wilkins, Baltimore, 1993.

Cohen A. Hematologic emergencies, in Textbook of Pediatric Emergency Medicine, 3rd edition, Fleisher G, Ludwig S, eds, Williams and Wilkins, Baltimore, 1993.

Cohen A. Iron overload, in The Sickle Hemoglobinopathies: Science and Medicine, Embury SH, Hebbel RP, Narla M, and Steinberg MH, eds, Raven Press, New York, 1994.

Himelstein B, Cohen A. Hematology, in Pediatric Secrets, 2nd edition, Polin RA and Ditmar MR, eds, Hanley and Belfus, Inc., Philadelphia, 1996.

Cohen AR, Manno CS. Neonatal anemia, in Intensive Care of the Fetus and Neonate, Spitzer A, ed, Mosby-Yearbook Publishing Company, St. Louis, 1996.

Cohen AR, Norris CF, Smith-Whitley K. Transfusion therapy for sickle cell disease, in New Directions in Pediatric Hematology, Capon SM and Chambers LA, editors, American Association of Blood Banks, Arlington, 1996.

McDonald-McGinn DM, LaRossa D, Goldmuntz E, Cohen A, Zackai EH. The 22q11.2 deletion: screening, diagnostic workup, and outcome of results; report on 181 patients. Genetic Testing 1:99-108, 1997.

Cohen AR, Manno CS. Transfusion practices in infants receiving assisted ventilation, in Clinics in Perinatology, Volume 25, Number 1, Carin Baniewicz, editor, W.B. Saunders Company, Philadelphia, 1998.

Cohen AR. Sickle cell disease - new treatments, new questions. N Engl J Med 339:42-44, 1998.

Arceci RJ, Reaman GH, Cohen AR, Lampkin BC. Case statement for the need to define pediatric hematology/oncology programs: a model of subspecialty care for chronic childhood diseases. J Pediatr Hematol Oncol 20:98-103, 1998.

Manno CS, Cohen AR. Neonatal Anemia: when to transfuse, in Current Pediatric Therapy 16, Burg FD, Wald ER, Ingelfinger JR, Polin RA, eds, W.B. Saunders Company, Philadelphia, 1999.

Cohen, AR. Choosing the best strategy to prevent childhood iron deficiency. JAMA 281:2247-2248, 1999.

Cohen A. Pallor, in Textbook of Pediatric Emergency Medicine, 4th edition, Fleisher G, Ludwig eds, Williams and Wilkins, Baltimore, 2000.

Cohen A. Purpura, in Textbook of Pediatric Emergency Medicine, 4th edition, Fleisher G, Ludwig S, eds, Williams and Wilkins, Baltimore, 2000.

Cohen A. Hematologic emergencies, in Textbook of Pediatric Emergency Medicine, 4th edition, Fleisher G, Ludwig S, eds, Williams and Wilkins, Baltimore, 2000.

Cohen, AR. Transfusional approaches to the management of iron overload, in Iron Chelators: New Development Strategies, Badman DG, Bergeron RJ, Brittenham GM, eds, The Saratoga Group, Ponte Vedra Beach, 2000.

Cohen A, Porter JB. Transfusion therapy, in Disorders of Hemoglobin, Forget BG, Higgs DR, Nagel RL, Steinberg MH, eds, Cambridge University Press, New York, 2001.

Fisher MJ, Cohen A. Normal red blood cell indices and differential diagnosis of anemia, Fetal and Neonatal Secrets, Polin RA, Spitzer AR, eds, Hanley and Belfus, Inc., Philadelphia, 2001.

Forget B, Cohen AR. Thalassemia Syndromes, in Hoffman R, Benz, Jr. EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds, Hematology: Basic Principles and Practice, 4/e. Church Livingstone, Philadelphia, 2004.

Kwiatkowski JL, Cohen AR. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias, Buchanan GR, ed, Hematology/Oncology Clinics of North America 18:1355-1377, 2004.

Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E: Thalassemia. Hematology (American Society Hematology Education Program): 14-34, 2004.

Cohen AR. New advances in chelation therapy. Hematology (American Society Hematology Education Program): 42-47, 2006.

Cohen AR. Pediatric Iron Overload. Advances in Hematology. Clinical Advances in Hematology & Oncology 5:601-602, 2007

Cohen, AR. Iron chelation therapy: you gotta have heart. Blood 115:2333-2334, 2010

Cohen A. Commentary: Concentrating the mind. Academic Medicine 86:546-547, 2011.

Books:

Sherwood W, Cohen A, editors. Transfusion Therapy: Fetus, Infant and Child. Masson Publishing USA, Inc., New York, 1980.

Cohen A, (guest editor). Perinatal Hematology, Seminars in Perinatology, Grune and Stratton, Inc., New York, 1983.

Cohen A, Lange B (guest editors). Hematology/Oncology Section, Current Opinion in Pediatrics, vol. 3, Current Science, Salem, 1991.

Cappellini MD, Cohen A, Porter J, Taher A, Viprikasit V: Guidelines for the Management of Transfusion-Dependent Thalassaemia, 3rd Edition, Thalassaemia International Federation, 2014

Heeney M, Cohen A, editors. Iron Disorders. Hematology-Oncology Clinics of North America, Elsevier Publishing, August 28, 2014

Grant Support:

PAST

H87-MC24055 (Kwiatkowski)	06/01/2012 – 05/31/2015	0.12 calendar
HRSA	$138,204	
Comprehensive Thalassemia Program		

The major goal of this project is to design and implement multi-center clinical research studies in thalassemia.

5 R01 HL095647-05 (Ware)	08/01/2009-07/31/2015	0.6 calendar
NIH/NHLBI	$80,640	

TCD with Transfusions Changing to Hydroxyurea

The major goal of this project is to compare transfusions with hydroxyurea and phlebotomy for the prevention of secondary stroke and the management of iron overload in children with sickle cell disease.

2 K12 HD043245-11 (Cohen, changed to St. Geme in 2013) 12/01/2012-11/30/2017
0.6 calendar
NIH/NICHD $432,000
CHOP Pediatric Scholars Program

The goal of this project is to provide pediatric physician-scientists who are junior faculty members with mentorship and resources to increase their research skills.

5 T32-HD43021-09 (Cohen) 05/01/2009-04/30/2014 0.0 calendar
CHOP Institutional Training in Pediatric Research $253,425

The goal of this project is to enhance the development of physician-scientists by providing mentorship and research training for fellows in pediatric subspecialties.

1U01 HL65232 (Cohen) 7/1/00 – 6/30/05 25%
NIH $268,235
The Mid-Atlantic Thalassemia Consortium

The major goal of this project is to design and implement multi-center clinical research studies in thalassemia.

R01-HL61185-01 (Cohen) 8/1/98 – 7/31/03 30%
NIH $209,189
Erythrocytapheresis to lower iron loading in thalassemia

The major goal of this project is to test the efficacy of erythrocytapheresis in lowering iron loading in patients with thalassemia.

R01-HL61182 (Wang) 9/30/98 – 7/31/01 10%
NIH $118,272
Quantitative Assessment of Iron Overload by MRI

The major goal of this project is to develop magnetic resonance techniques to assess body iron stores.

CDC U27-CCU313193-03 (Cohen) 9/30/96 – 9/29/01 5%
Centers for Disease Control $66,059
Prevention of Complications of Hemophilia

The major goal of this project is to develop strategies to prevent complications of hemophilia and its treatment in children with bleeding disorders, with special emphasis on inhibitors, hepatitis, and joint disease.

MCJ 422007-09 (Cohen) 10/1/96 – 5/31/01 0%
Maternal Child Health Bureau $46,905
Regional Hemophilia Diagnostic and Treatment Center

The major goal of this project is to provide comprehensive, multidisciplinary, culturally competent family-centered care to children with bleeding disorders and their families.

P01 HL64190 (High) 12/1/99 – 11/30/04 20%
NIH/NHLBI $259,623
Gene Therapy for Hemophilia (PPG)
Project 4: Human application of AAV-mediated muscle-directed factor IX gene transfer. The major goal of this project is to conduct a clinical trial of gene therapy for hemophilia B.